Genetics. Research on the causes, diagnosis, and treatment of chronic myelomonocytic leukemia (CMML) is being done at many cancer research centers. Scientists are making progress in understanding which changes in a person's DNA and RNA can cause normal bone marrow cells to develop into leukemia cells.
About Chronic Myelogenous Leukemia: Chronic Myelogenous Leukemia is cancer that starts inside bone marrow. Chronic Myelogenous Leukemia causes an uncontrolled growth of immature cells that make a certain type of white blood cell called myeloid cells. The diseased cells build up in the bone marrow and blood.
Treatment for Chronic Myelomonocytic Leukemia (CMML) Our physicians are part of a multidisciplinary team whose approach to cancer and blood disorders is to personalize the treatment plan for each patient and to treat them holistically, focusing on the whole person and not just on their disease.
This page lists cancer drugs approved by the FDA for use in leukemia. The drug names link to NCI's Cancer Drug Information summaries. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters.
Cancer therapy for chronic myelomonocytic leukemia (CMML) can sometimes produce side effects. For most patients, treatment side effects are temporary and go away once therapy ends. For other patients, side effects can be more severe, sometimes requiring hospitalization. Some patients never have any side effects.
If you're being treated for chronic myelomonocytic leukemia (CMML), your first line of defense may be chemotherapy. During chemotherapy, you'll be given potent drugs that must be toxic enough to damage or kill the cancer cells. At the same time, these drugs take aim at normal cells and cause side effects.
Diagnosis and treatment of CMML. Find out about how chronic myelomonocytic leukaemia (CMML) is diagnosed and the treatment you might have. You can also get tips about coping with this rare condition. Diagnosing CMML. Most people are diagnosed because doctors find abnormal monocytes during a blood test for something else.
TAMPA, Fla. (July 24, 2013) – Moffitt Cancer Center researchers are recruiting chronic myelomonocytic leukemia patients to test the effectiveness of the drug ruxolitinib. Chronic myelomonocytic leukemia, a genetically diverse malignancy that can transform into acute myeloid leukemia, is an aggressive disease with a three-year survival rate of 20 percent.
Stem cell transplant (SCT) is the only way to cure patients with chronic myelomonocytic leukemia (CMML). It may be the treatment of choice for younger patients when a matched donor is available. Advances in SCT processes mean this treatment could also be an option for some older patients.
Drug Therapy. For the 1 percent to 4 percent of CMML patients who have the PDGFR-β and TEL gene mutation, imatinib mesylate (brand name: Gleevec®) can be an effective treatment. Gleevec has been used successfully to control chronic myeloid leukemia. The drug is swallowed in tablet form.